Valopicitabine

Drug Profile

Valopicitabine

Alternative Names: NM 107; NM-283; NMC-283; val-mCyd

Latest Information Update: 08 Jan 2015

Price : $50

At a glance

  • Originator Idenix Pharmaceuticals; University of Cagliari
  • Developer Idenix Pharmaceuticals
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 08 Aug 2007 Discontinued -Phase-I/II clinical trials in Hepatitis C (Treatment-naive) in Puerto Rico (PO) (NCT00120835)
  • 08 Aug 2007 Discontinued - Phase-II for Hepatitis C treatment in USA (PO)
  • 17 Jul 2007 Suspended - Phase-II for Hepatitis C treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top